A revolutionary new treatment that will save lives


Up until now P. vivax malaria most commonly found in Southeast Asia and Latin America has been treated with a 14-day course of treatment for radical cure – many patients never complete the full course of treatment which increases the chance of a relapse. British pharmaceutical company GlaxoSmithKline (GSK) has pioneered a revolutionary new treatment that will cure the infection with a single dose.

Working in partnership with MMV, they have developed a drug known as tafenoquine (Kozenis®/Krintafel®), It is the first-ever antimalarial treatment to be delivered as a single dose for the prevention of relapse of P.vivax malaria, which looks set to combat the challenges posed by previous medicines and improve the process for patients.